MEKINIST, also known by its generic name trametinib, is a targeted therapy medication used in the treatment of certain types of cancer. It is specifically designed to inhibit the activity of a protein known as MEK, which plays a crucial role in the MAPK/ERK pathway, a signaling pathway that helps control cell division and survival. By blocking this pathway, MEKINIST can help slow down or stop the growth of cancer cells. It is commonly used for the treatment of melanoma with a specific genetic mutation (BRAF V600E or V600K mutations) and may be used alone or in combination with other medications. MEKINIST has been approved by regulatory agencies in various countries for its efficacy and safety in treating patients with specific cancer types, offering hope for improved outcomes.